Innospec Inc (IOSP)
Official siteBASIC MATERIALS • SPECIALTY CHEMICALS • NASDAQ
Market Cap: $1.98B
Last updated: Nov 17, 2026 at 11:06 AM ET
Innospec Inc (IOSP) Financials: Revenue, Profit and Cash Flow
Innospec reported revenue of $1.78B for the fiscal year ended Dec 31, 2025, down 3.7% from the year before. That year, net income was $116.60M with a net margin of 6.6%, operating cash flow was $138.30M and free cash flow was $62.80M. The quarter ended Sep 30, 2026 had revenue of $473.60M and net income of $31.60M.
Revenue and Margins
The operating margin was 7.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $883.40M, a compound annual rate of 8.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.78B | -3.7% | 27.7% | 7.3% | 6.6% |
| Dec 2024 | $1.85B | -5.3% | 29.4% | 9.6% | 1.9% |
| Dec 2023 | $1.95B | -0.8% | 30.3% | 8.3% | 7.1% |
| Dec 2022 | $1.96B | +32.4% | 29.9% | 9.5% | 6.8% |
| Dec 2021 | $1.48B | +24.3% | 29.3% | 8.9% | 6.3% |
| Dec 2020 | $1.19B | -21.2% | 28.7% | 2.8% | 2.4% |
| Dec 2019 | $1.51B | +2.5% | 30.8% | 9.9% | 7.4% |
| Dec 2018 | $1.48B | +13.0% | 29.5% | 9.0% | 5.8% |
| Dec 2017 | $1.31B | +47.9% | 30.9% | 9.6% | 4.7% |
| Dec 2016 | $883.40M | N/A | 37.6% | 11.1% | 9.2% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 227.5% from the year before. In the quarter ended Sep 2026, net income rose 148.8% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.78B | $1.85B | $1.95B | $1.96B | $1.48B | $1.19B | $1.51B | $1.48B | $1.31B | $883.40M |
| Cost of revenue | $1.29B | $1.30B | $1.36B | $1.38B | $1.05B | $850.40M | $1.05B | $1.04B | $903.50M | $551.10M |
| Gross profit | $492.40M | $542.90M | $591.10M | $586.70M | $434.90M | $342.70M | $466.20M | $435.00M | $403.30M | $332.30M |
| Research and development | $51.00M | $56.50M | $49.00M | $38.70M | $37.40M | $30.90M | $35.40M | $33.40M | $31.40M | $25.40M |
| Operating income | $129.50M | $177.90M | $161.60M | $187.30M | $132.10M | $33.70M | $149.90M | $133.50M | $125.00M | $98.20M |
| Net income | $116.60M | $35.60M | $139.10M | $133.00M | $93.10M | $28.70M | $112.20M | $85.00M | $61.80M | $81.30M |
| EBITDA | $172.50M | N/A | $211.40M | $225.80M | $178.60M | $87.50M | $202.80M | $188.10M | $186.70M | $144.40M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $473.60M | $491.40M | $453.20M | $455.60M | $441.90M | $439.70M | $440.80M | $466.80M | $443.40M | $435.00M | $500.20M | $494.70M |
| Gross profit | $129.10M | $138.30M | $123.50M | $127.40M | $116.70M | $123.20M | $125.10M | $136.20M | $124.10M | $126.90M | $155.70M | $155.70M |
| Operating income | $41.70M | $39.70M | $36.50M | $46.80M | $5.90M | $34.30M | $42.50M | $41.10M | $45.60M | $40.70M | $50.50M | $44.50M |
| Net income | $31.60M | $31.20M | $30.80M | $47.40M | $12.70M | $23.90M | $33.60M | -$70.40M | $33.40M | $31.20M | $41.40M | $37.80M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $7.00M by $285.50M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.83B | $1.73B | $1.71B | $1.60B | $1.57B | $1.40B | $1.47B | $1.47B | $1.41B | $1.18B |
| Current assets | $1.00B | $956.60M | $885.70M | $872.60M | $728.10M | $566.20M | $630.30M | $663.90M | $0 | $441.10M |
| Cash and equivalents | $292.50M | $289.20M | $203.70M | $147.10M | $141.80M | $105.30M | $75.70M | $123.10M | $90.20M | $101.90M |
| Total liabilities | $499.50M | $518.60M | $557.80M | $563.30M | $537.90M | $452.50M | $549.90M | $647.90M | $48.60M | $527.60M |
| Short-term debt | $7.00M | $0 | $13.60M | $13.90M | $12.50M | $11.80M | $1.00M | $23.20M | $18.50M | $11.90M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | $58.60M | $186.20M | $202.60M | $258.50M |
| Shareholder equity | $1.33B | $1.21B | $1.15B | $1.04B | $1.03B | $944.40M | $918.50M | $825.00M | $794.30M | $653.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.86B | $1.85B | $1.82B | $1.83B | $1.80B | $1.81B | $1.77B | $1.73B | $1.80B | $1.70B | $1.73B | $1.71B |
| Total liabilities | $476.30M | $495.20M | $467.60M | $499.50M | $496.50M | $504.60M | $508.90M | $518.60M | $550.10M | $504.40M | $546.60M | $557.80M |
| Cash and equivalents | $251.90M | $250.20M | $289.10M | $292.50M | $270.80M | $266.60M | $299.80M | $289.20M | $303.80M | $240.20M | $270.10M | $203.70M |
| Shareholder equity | $1.37B | $1.34B | $1.34B | $1.33B | $1.30B | $1.30B | $1.26B | $1.21B | $1.24B | $1.19B | $1.18B | $1.15B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 45.4% of operating cash flow. Dividends and share repurchases together came to 105.6% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $138.30M | $184.50M | $207.30M | $81.70M | $93.20M | $145.90M | $161.60M | $104.90M | $82.70M | $105.50M |
| Capital expenditures | $75.50M | $62.30M | $77.20M | $42.30M | $39.10M | $29.70M | $31.00M | $30.10M | $28.00M | $16.50M |
| Free cash flow | $62.80M | $122.20M | $130.10M | $39.40M | $54.10M | $116.20M | $130.60M | $74.80M | $54.70M | $89.00M |
| Dividends paid | $42.40M | $38.80M | $35.10M | $31.70M | $28.80M | $25.60M | $25.00M | $21.70M | $18.60M | $59.90M |
| Share repurchases | $23.90M | $700.00K | $1.10M | $5.90M | $800.00K | $2.10M | $2.40M | $1.40M | $1.10M | $8.40M |
| Investing cash flow | -$75.10M | -$62.00M | -$111.80M | -$42.10M | -$36.20M | -$29.70M | -$31.00M | -$35.50M | -$29.60M | -$209.10M |
| Financing cash flow | -$63.90M | -$35.30M | -$39.00M | -$33.70M | -$20.00M | -$86.80M | -$177.90M | -$36.20M | -$66.40M | $69.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $17.40M | $7.20M | $17.60M | $61.40M | $39.10M | $10.50M | $28.30M | $25.70M | $73.50M | $4.70M | $80.60M | $72.40M |
| Capital expenditures | $15.80M | $17.70M | $14.00M | $21.20M | $22.10M | $16.60M | $15.60M | $20.80M | $11.80M | $15.30M | $14.40M | $21.20M |
| Free cash flow | $1.60M | -$10.50M | $3.60M | $40.20M | $17.00M | -$6.10M | $12.70M | $4.90M | $61.70M | -$10.60M | $66.20M | $51.20M |
Frequently Asked Questions About IOSP
What is Innospec's annual revenue?
Innospec reported revenue of $1.78B for the fiscal year ended Dec 31, 2025.
How fast is Innospec's revenue growing?
Revenue was down 3.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -3.3%.
Is Innospec profitable?
Yes. Innospec reported net income of $116.60M for the fiscal year ended Dec 31, 2025, with a net margin of 6.6%.
How much free cash flow does IOSP generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $138.30M minus capital expenditures of $75.50M produced free cash flow of $62.80M.
How much debt does Innospec have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $7.00M and cash and equivalents of $292.50M.
IOSP pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors